ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lanifibranor

Also written as “IVA337” and “Lanifibranor”.

In Sino Biopharmaceutical’s pipeline, 泛PPAR激动剂. Its studies are mostly in Non-alcoholic Fatty Liver Disease · Scleroderma, Diffuse, led by 2 companies.

Drug pageLanifibranor: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 16, 20216 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Inventiva Pharmaits history only51 open or runningphase 3since Apr 16, 2021Jun 30, 2015none ahead
Sino Biopharmaceutical10 open or runningphase 1since Nov 7, 2023Nov 7, 2023none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as Lanifibranor, phase 3, as of Nov 16, 2026 (source).

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sino Biopharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2016Named lanifibranorINNProposed as its International Nonproprietary Name in WHO's List 116 · before, IVA337
  2. Nov 7, 2023First study: phase 1 study in PharmacokineticFirst studyNCT06126562 · 24 enrolled · China

TargetBeta

“泛PPAR激动剂”the company's pipeline, read by Claude · source

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
chiglitazarruleChipscreen Biosciencesphase 39

Studies

The one study Sino Biopharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06126562Pharmacokinetic · China1CompletedNov 28, 202324

How it is read

Names in the registry

  • “IVA337”, 4 entries
  • “Lanifibranor”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.